Home 2018-04-18T11:34:10+00:00

Relaxin to help people with cardio-metabolic disease

Relaxera’s goal is to develop synthetic human Relaxin-2 for the chronic treatment of the aging heart, Heart Failure with preserved Ejection Fraction (HFpEF), and impaired glucose tolerance.

Learn more

WELCOME TO RELAXERA

Relaxera Pharmazeutische Gesellschaft mbH & Co. KG (“Relaxera”) is a company dedicated to the development of pharmaceuticals and treatments with human relaxin-2 for chronic cardiovascular diseases and (pre-)diabetic conditions.

Learn More

VISION & STRATEGY

Relaxera Pharmazeutische Gesellschaft mbH & Co. KG (“Relaxera”) is a company dedicated to the development of pharmaceuticals and treatments with…

Learn more

PATENTS

Relaxera has taken all necessary actions to protect its intellectual property and ongoing developments. To date, Relaxera owns 17 patents or patent applications…

Learn more

OWNERS & ADVISERS

The founders of Relaxera are a community of physicians, biochemists and pharmacologists with many years of experience in research and practice.

Learn more

NEWS AND EVENTS

COOPERATIONS AND PROJECTS

HFpEF – Heart Failure with preserved Ejection Fraction

HFpEF represents a distinct sub-entity of heart failure. Like heart failure in general, HFpEF is characterized by the inability of the heart to provide, at normal filling pressures, an output adequate to meet the physiologically varying demands of the body (Paulus 2007, The Task Force 2008). …

Learn more